Thomson and other developers of the new alchemy emphasize that embryonic stem cells remain invaluable research tools and will be crucial for confirming that iPS cells harbor no hidden limitations. Reprogrammed cells “might differ in clinically relevant ways from embryonic stem cells,” Thomson notes. “People want to rush and say we don’t need embryonic stem cells anymore, and over time that might be true, but right now that’s premature.”
This article was originally published with the title Potent Alternative.
Subscribe
Buy This Issue
Already a Digital subscriber? Sign-in Now
If your institution has site license access, enter here.
Already a Digital subscriber? Sign-in Now
If your institution has site license access, enter here.
See what we're tweeting about
Comments
Add Comment